Hormonal
Anabolic androgenic steroids (AAS) used for bodybuilding cause a distinct phenotype of liver injury characterized by high bilirubin levels with relatively low transaminases, often leading to cholestasis and liver neoplasms.
If you are using anabolic steroids for bodybuilding, be aware that they can cause serious liver damage, including cholestasis, liver tumors, and acute liver failure. Symptoms may include jaundice (yellowing of skin/eyes) and abdominal pain. Regular liver function monitoring is crucial, and you should discuss your steroid use with a healthcare provider.
AAS hepatotoxicity was associated with a distinct phenotype, characterized by considerable total bilirubin (TB) elevations independent of type of damage, in addition to low values of transaminases and alkaline phosphatase... Several patterns of injury such as focal nodular hyperplasia, hepatocellular adenoma, hepatocellular carcinoma, peliosis hepatis... have been described.
Why this rating
Evidence is based on registry data and case series, showing a clear trend but lacking large-scale controlled studies.
Source
Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics
Miren García‐Cortés et al. · International Journal of Molecular Sciences · 2016
DOI 10.3390/ijms17040537
More from this paper
- Dietary supplements, particularly multi-ingredient weight loss products and illicit anabolic steroids, are a significant and increasing cause of drug-induced liver injury (DSILI), often leading to acute liver failure and transplantation.Moderate
- Green tea extract, particularly in concentrated supplement form, can cause hepatocellular liver injury, including acute liver failure requiring transplantation, whereas green tea infusion is generally safe.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →